Universal DNA screening in endometrial cancer reveals hidden genetic risks
NCT ID NCT03460483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested over 1,000 women with endometrial cancer for DNA repair problems that can be inherited (Lynch syndrome). By analyzing tumor DNA, researchers aimed to personalize cancer treatment and identify family members who might also be at risk. The goal was to improve care and outcomes for patients and their relatives.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aultman Health Foundation
Canton, Ohio, 44710, United States
-
Mercy Health - St. Vincent Medical Center
Toledo, Ohio, 43608, United States
-
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
-
Ohio Health
Columbus, Ohio, 43214, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304, United States
-
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45245, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a natural compound boost chemotherapy against endometrial cancer?
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a walking routine alter cancer biomarkers? new trial investigates
- Could a lighter immunotherapy schedule keep advanced cancers in check?